Loading...
 
Mediterr J Rheumatol 2019;30(3);141-6
Twenty Years of Targeted Treatment in Rheumatoid Arthritis in the Greek Databases: Achievements and Unmet Needs
Authors Information
1Department of Rheumatology and Clinical Immunology, School of Medicine, University of Crete, Greece
2First Department of Propaedeutic and Internal Medicine & Rheumatology Unit, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
34th Department of Internal Medicine, School of Medicine, National & Kapodistrian University of Athens, Athens, Greece
4nd Department of Medicine and Laboratory, Hippokration General Hospital, Medical School, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
5Joint Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
6Laboratory of Rheumatology, Inflammation and Autoimmunity, Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology, Heraklion, Greece
7Laboratory of Immune Regulation and Tolerance, Autoimmunity and Inflammation, Biomedical Research Foundation of the Academy of Athens, Athens, Greece
References
  1. Anagnostopoulos I, Zinzaras E, Alexiou I, Papathanasiou AA, Davas E, Koutroumpas A, et al. The prevalence of rheumatic diseases in central Greece: a population survey. BMC Musculoskelet Disord 2010;11:98. [https://doi.org/10.1186/1471-2474-11-98] [PMID: 20504294] [PMCID: PMC2890601]
  2. Andrianakos A, Trontzas P, Christoyannis F, Kaskani E, Nikolia Z, Tavaniotou E, et al. Prevalence and management of rheumatoid arthritis in the general population of Greece--the ESORDIG study. Rheumatology (Oxford) 2006;45(12):1549-54. [https://doi.org/10.1093/rheumatology/kel140] [PMID: 16690763]
  3. Drosos AA, Alamanos I, Voulgari PV, Psychos DN, Katsaraki A, Papadopoulos I, et al. Epidemiology of adult rheumatoid arthritis in northwest Greece 1987-1995. J Rheumatol 1997;24(11):2129-33. [PMID: 9375871]
  4. Drosos AA, Lanchbury JS, Panayi GS, Moutsopoulos HM. Rheumatoid arthritis in Greek and British patients. A comparative clinical, radiologic, and serologic study. Arthritis Rheum 1992;35(7):745-8. [PMID: 1622412]
  5. Boubouchairopoulou N, Flouri I, Drosos AA, Boki K, Settas L, Zisopoulos D, et al. Treatment with the first TNF inhibitor in rheumatoid arthritis patients in the Hellenic Registry of Biologic Therapies improves quality of life especially in young patients with better baseline functional status. Clin Exp Rheumatol 2016;34(6):999-1005. [PMID: 27749220]
  6. Flouri I, Drosos A, Boki K, Skopouli F, Karras D, Papadopoulos I, et al. Geriatric rheumatoid arthritis patients on delayed anti-TF-alpha agents have higher disease activity and experience more often serious adverse events compared to younger adults. Clin Exp Rheumatol 2009;27(5):705-6.
  7. Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, et al. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Semin Arthritis Rheum 2014;43(4):447-57. [https://doi.org/10.1016/j.semarthrit.2013.07.011] [PMID: 24012040]
  8. Flouri ID, Markatseli TE, Boki KA, Papadopoulos I, Skopouli FN, Voulgari PV, et al. Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence. J Rheumatol 2018;45(6):785-94. [https://doi.org/10.3899/jrheum.170477] [PMID: 29606666]
  9. Genitsaridi I, Flouri I, Repa A, Avgoustidis N, Kougkas N, Papalopoulos I, et al. In Clinical Practice a Substantial Group of Rheumatoid Arthritis (RA) Patients on Biologic Therapy (bDMARDs) Has Persistent Moderate Disease Activity Despite Treatment Switches That Correlates with Unfavourable Long-Term Outcome. Arthritis Rheumatol 2018;70. [https://doi.org/10.1177/1759720X16665330]
  10. Argoustidis N, Flouri I, Adamichou C, Kabouraki E, Eskitzis A, Kyfonidou P, et al. FRI0244 Low Dose of Rituximab Is Effective for Maintenance of Clinical Remission or Low Disease Activity in Patients with Rheumatoid Arthritis [abstract]. Ann Rheum Dis 2017;76:577.
  11. Flouri I, Repa A, Avgoustidis N, Kougkas N, Fanouriakis A, Papalopoulos I, et al. FRI0236 After discontinuation of the first tumor necrosis factor inhibitor (TNFi), non-TNFi biologic agents have similar responses but higher retention rates compared to a second course of a different TNFi: long-term prospective observational study of patients with rheumatoid arthritis in a tertiary hospital of Greece [abstract]. Ann Rheum Dis 2017;76(Suppl 2):574. [https://doi.org/10.1136/annrheumdis-2017-eular.6817]
  12. Flouri I, Repa A, Avgoustidis N, Kougkas N, Fanouriakis A, Papalopoulos I, et al. SAT0204 Abatacept survival in rheumatoid arthritis patients at 2 years is 59%; its use as a 2nd line biologic agent and lower baseline HAQ predict better survival in clinical practice: a prospective, observational single center study. Ann Rheum Dis 2017;76(Suppl 2): 850. [Abstract] [https://doi.org/10.1136/annrheumdis-2017-eular.6931]
  13. Flouri I, Repa A, Fanouriakis A, Kougkas N, Papalopoulos I, Kampouraki E, et al. Abatacept-Treated Rheumatoid Arthritis Patients Have Better Drug-Survival Rate When Abatacept Is the First or Second Line Biologic Agent with an Excellent Overall Safety Profile: A Single Center Experience [abstract]. Arthritis Rheumatol 2015;67(Suppl 10).
  14. Goutakoli P, Papadaki G, Bertsias G, Repa A, Kampouraki H, Avgoustidis N, et al. Baseline Levels of Il-17-Producing Cd4(+) T Cells Predict Clinical Response to Abatacept in Rheumatoid Arthritis Patients [abstract]. Ann Rheum Dis 2018;77:A20. [http://doi.org/10.1136/annrheumdis-2018-EWRR2018.41]
  15. Nakou M, Katsikas G, Sidiropoulos P, Bertsias G, Papadimitraki E, Raptopoulou A, et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther 2009;11(4):R131. [https://doi.org/10.1186/ar2798] [PMID: 19715572] [PMCID: PMC2745815]
  16. Papalopoulos I, Fanouriakis A, Kougkas N, Flouri I, Sourvinos G, Bertsias G, et al. Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study. Clin Exp Rheumatol 2018;36(1):102-9. [PMID 28850029]
  17. Sfikakis PP, Bournia VK, Sidiropoulos P, Boumpas DT, Drosos AA, Kitas GD, et al. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database. Clin Exp Rheumatol 2017;35(4):579-85. [PMID: 28281458]
  18. Lazarini A, Thomas K, Kaltsonoudis E, Drosos A, Tsatsani P, Gazi S, et al. AB0421 Low rates of retention of biologic DMARD monotherapy in patients with rheumatoid arthritis in real life settings [abstract]. Ann Rheum Dis 2018;77:1374. [https://doi.org/10.1136/annrheumdis-2018-eular.5780]
  19. Thomas K, Lazarini A, Kaltsonoudis E,  Drosos A, Tsatsani P, Gazi S, et al. THU0102 High rates of residual disease activity despite current therapies in a real life rheumatoid arthritis cohort: Data from 1096 patients [abstract]. Ann Rheum Dis 2018; 77:272-3. [https://doi.org/10.1136/annrheumdis-2018-eular.6944]
  20. Thomas K, Kaltsonoudis E, Drosos A, Papalopoulos I, Sidiropoulos P, Katsimbri P, et al. SAT0176 Patterns of biologic DMARD monotherapy in a large nationwide rheumatoid arthritis cohort: Data from 1036 patients [abstract]. Ann Rheum Dis 2017;76:836-7. [http://doi.org/10.1136/annrheumdis-2017-eular.4390]
  21. Thomas K, Lazarini A, Kaltsonoudis E, Drosos A, Katsimbri P, Boumpas D, et al. SAT0118 Dyslipidemia is undertreated in patients with rheumatoid arthritis: Results from a large cohort of RA patients in daily clinical practice [abstract]. Ann Rheum Dis 2016;75 (Suppl 2):708. [https://doi.org/10.1136/annrheumdis-2016-eular.5475]
  22. Thomas K, Lazarini A, Kaltsonoudis E, Drosos AA, Papalopoulos I, Sidiropoulos P, et al. Multicenter Cross-sectional Study of Patients with Rheumatoid Arthritis in Greece: Results from a cohort of 2.491 patients. Mediterr J Rheumatol 2018;29(1):27-37. [https://doi.org/10.31138/mjr.29.1.27]
  23. Arida A, Protogerou AD, Konstantonis G, Fragiadaki K, Kitas GD, Sfikakis PP. Atherosclerosis is not accelerated in rheumatoid arthritis of low activity or remission, regardless of antirheumatic treatment modalities. Rheumatology (Oxford) 2017;56(6):934-9. [https://doi.org/10.1093/rheumatology/kew506] [PMID: 28160488]
  24. Arida A, Zampeli E, Konstantonis G, Fragiadaki K, Kitas GD, Protogerou AD, et al. Rheumatoid arthritis is sufficient to cause atheromatosis but not arterial stiffness or hypertrophy in the absence of classical cardiovascular risk factors. Clin Rheumatol 2015;34(5):853-9. [https://doi.org/10.1007/s10067-015-2914-1] [PMID: 25754335]
  25. Bamias G, Stamatelopoulos K, Zampeli E, Protogerou A, Sigala F, Papamichael C, et al. Circulating levels of TNF-like cytokine 1A correlate with the progression of atheromatous lesions in patients with rheumatoid arthritis. Clin Immunol 2013;147(2):144-50. [https://doi.org/10.1016/j.clim.2008.07.014] [PMID: 18757243]
  26. Karvounaris SA, Sidiropoulos PI, Papadakis JA, Spanakis EK, Bertsias GK, Kritikos HD, et al. Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study. Ann Rheum Dis 2007;66(1):28-33. [https://doi.org/10.1136/ard.2006.053488] [PMID: 16793841] [PMCID: PMC1798406]
  27. Mavrogeni S, Dimitroulas T, Sfikakis PP, Kitas GD. Heart involvement in rheumatoid arthritis: multimodality imaging and the emerging role of cardiac magnetic resonance. Semin Arthritis Rheum 2013;43(3):314-24. [https://doi.org/10.1016/j.semarthrit.2013.05.001] [PMID: 23786873]
  28. Papadakis JA, Sidiropoulos PI, Karvounaris SA, Vrentzos GE, Spanakis EK, Ganotakis ES, et al. High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNFalpha treatment: correlation with disease activity. Clin Exp Rheumatol 2009;27(2):292-8. [PMID: 19473571]
  29. Protogerou A, Zampeli E, Tentolouris N, Makrilakis K, Kitas G, Sfikakis PP. Subclinical femoral atheromatosis in rheumatoid arthritis: comparable prevalence to diabetes mellitus in a case-control study. Ann Rheum Dis 2012;71(9):1534-6. [https://doi.org/10.1136/annrheumdis-2011-201278] [PMID: 22764043]
  30. Protogerou AD, Fransen J, Zampeli E, Argyris AA, Aissopou E, Arida A, et al. The Additive Value of Femoral Ultrasound for Subclinical Atherosclerosis Assessment in a Single Center Cohort of 962 Adults, Including High Risk Patients with Rheumatoid Arthritis, Human Immunodeficiency Virus Infection and Type 2 Diabetes Mellitus. PLoS One 2015;10(7):e0132307. [https://doi.org/10.1371/journal.pone.0132307] [PMID: 26230728] [PMCID: PMC4521696]
  31. Protogerou AD, Kitas GD, Sfikakis PP. Importance of standardized methodology to comparisons between studies of rheumatoid arthritis and cardiovascular disease: comment on the article by Giles et al. Arthritis Rheum 2012;64(10):3487-8; author reply 8. [https://doi.org/10.1002/art.34612] [PMID: 22777506]
  32. Protogerou AD, Panagiotakos DB, Zampeli E, Argyris AA, Arida K, Konstantonis GD, et al. Arterial hypertension assessed "out-of-office" in a contemporary cohort of rheumatoid arthritis patients free of cardiovascular disease is characterized by high prevalence, low awareness, poor control and increased vascular damage-associated "white coat" phenomenon. Arthritis Res Ther 2013;15(5):R142. [https://doi.org/10.1186/ar4324] [PMID: 24286134] [PMCID: PMC3978881]
  33. Sfikakis PP, Bournia VK, Kitas G. Do non-steroidal anti-inflammatory drugs increase or decrease cardiovascular risk in patients with rheumatoid arthritis? Clin Exp Rheumatol 2014;32(6 Suppl 87):S-8-9. [PMID: 25327337]
  34. Sidiropoulos PI, Karvounaris SA, Boumpas DT. Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology, and clinical implications. Arthritis Res Ther 2008;10(3):207. [https://doi.org/10.1186/ar2397] [PMID: 18492218] [PMCID: PMC2483433]
  35. Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 2006;33(12):2440-6. [PMID: 17014005]
  36. Stagakis I, Bertsias G, Karvounaris S, Kavousanaki M, Virla D, Raptopoulou A, et al. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther 2012;14(3):R141. [https://doi.org/10.1186/ar3874] [PMID: 22691241] [PMCID: PMC3446524]
  37. Stamatelopoulos KS, Kitas GD, Papamichael CM, Chryssohoou E, Kyrkou K, Georgiopoulos G, et al. Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscler Thromb Vasc Biol 2009;29(10):1702-8. [https://doi.org/10.1161/ATVBAHA.109.190108] [PMID: 19608975]
  38. Stamatelopoulos KS, Kitas GD, Papamichael CM, Kyrkou K, Zampeli E, Fragiadaki K, et al. Subclinical peripheral arterial disease in rheumatoid arthritis. Atherosclerosis 2010;212(1):305-9. [https://doi.org/10.1016/j.atherosclerosis.2010.05.007] [PMID: 20553683]
  39. Toutouzas K, Sfikakis PP, Karanasos A, Aggeli C, Felekos I, Kitas G, et al. Myocardial ischaemia without obstructive coronary artery disease in rheumatoid arthritis: hypothesis-generating insights from a cross-sectional study. Rheumatology (Oxford) 2013;52(1):76-80. [https://doi.org/10.1093/rheumatology/kes349] [PMID: 23185038]
  40. Zampeli E, Protogerou A, Stamatelopoulos K, Fragiadaki K, Katsiari CG, Kyrkou K, et al. Predictors of new atherosclerotic carotid plaque development in patients with rheumatoid arthritis: a longitudinal study. Arthritis Res Ther 2012;14(2):R44. [https://doi.org/10.1186/ar3757] [PMID: 22390577] [PMCID: PMC3446411]
  41. Welsing PM, Landewe RB, van Riel PL, Boers M, van Gestel AM, van der Linden S, et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 2004;50(7):2082-93. [https://doi.org/10.1002/art.20350] [PMID: 15248205]
  42. Cordtz R, Hawley S, Prieto-Alhambra D, Hojgaard P, Zobbe K, Kristensen LE, et al. Reduction in Upper Limb Joint Surgery among Rheumatoid Arthritis Patients: An Interrupted Time Series Analysis using Danish Health Care Registers. Arthritis Care Res (Hoboken) 2019. [https://doi.org/10.1002/acr.23835] [PMID: 30680930]
  43. Singh S, Fumery M, Singh AG, Singh N, Prokop LJ, Dulai PS, et al. Comparative Risk of Cardiovascular Events with Biologic and Synthetic Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis. Arthritis Care Res (Hoboken) 2019. [https://doi.org/10.1002/acr.23875] [PMID: 30875456]